Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib in KIF5B-RET-positive lung adenocarcinoma
jRCT2080222692Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Dec 2014
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib in Non-small cell lung cancer adenocarcinoma (NSCLC), sponsored by Eisai Co., Ltd. Started Dec 2014; status: completed.
02
Drugs
lenvatinib
03
Conditions
Non-small cell lung cancer adenocarcinoma (NSCLC)
Beyond the preview
Go deeper on jRCT2080222692.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222692.